Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 17 studies | 26% ± 10% | |
astrocyte | 10 studies | 27% ± 12% | |
macrophage | 9 studies | 26% ± 10% | |
epithelial cell | 8 studies | 34% ± 17% | |
adipocyte | 8 studies | 21% ± 5% | |
fibroblast | 8 studies | 22% ± 5% | |
oligodendrocyte | 8 studies | 27% ± 8% | |
microglial cell | 7 studies | 25% ± 8% | |
ciliated cell | 6 studies | 23% ± 7% | |
basal cell | 6 studies | 30% ± 16% | |
endothelial cell of lymphatic vessel | 6 studies | 28% ± 9% | |
glutamatergic neuron | 5 studies | 43% ± 23% | |
oligodendrocyte precursor cell | 5 studies | 29% ± 11% | |
myeloid cell | 5 studies | 23% ± 6% | |
cardiac muscle cell | 5 studies | 30% ± 5% | |
dendritic cell | 5 studies | 21% ± 9% | |
type I pneumocyte | 5 studies | 23% ± 6% | |
CD4-positive, alpha-beta T cell | 4 studies | 19% ± 1% | |
non-classical monocyte | 4 studies | 27% ± 7% | |
neuron | 4 studies | 25% ± 13% | |
lymphocyte | 4 studies | 25% ± 7% | |
type II pneumocyte | 4 studies | 19% ± 5% | |
GABAergic neuron | 4 studies | 41% ± 15% | |
club cell | 4 studies | 22% ± 7% | |
T cell | 4 studies | 19% ± 3% | |
natural killer cell | 4 studies | 19% ± 2% | |
pericyte | 4 studies | 21% ± 5% | |
smooth muscle cell | 4 studies | 19% ± 2% | |
goblet cell | 4 studies | 29% ± 16% | |
interneuron | 4 studies | 36% ± 21% | |
classical monocyte | 3 studies | 23% ± 5% | |
CD8-positive, alpha-beta T cell | 3 studies | 19% ± 2% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 18% ± 1% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 18% ± 1% | |
retina horizontal cell | 3 studies | 19% ± 3% | |
hepatocyte | 3 studies | 36% ± 26% | |
abnormal cell | 3 studies | 29% ± 13% | |
alveolar macrophage | 3 studies | 29% ± 9% | |
monocyte | 3 studies | 25% ± 3% | |
transit amplifying cell | 3 studies | 35% ± 22% | |
gamma-delta T cell | 3 studies | 21% ± 4% | |
mucosal invariant T cell | 3 studies | 19% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 5884.06 | 459 / 459 | 100% | 54.93 | 1118 / 1118 |
esophagus | 100% | 5586.90 | 1445 / 1445 | 100% | 47.81 | 183 / 183 |
lung | 100% | 5313.02 | 578 / 578 | 100% | 45.35 | 1155 / 1155 |
ovary | 100% | 4602.59 | 180 / 180 | 100% | 27.38 | 430 / 430 |
prostate | 100% | 5253.56 | 245 / 245 | 100% | 43.49 | 502 / 502 |
stomach | 100% | 4630.06 | 359 / 359 | 100% | 51.57 | 286 / 286 |
intestine | 100% | 5627.78 | 966 / 966 | 100% | 56.78 | 526 / 527 |
bladder | 100% | 5509.38 | 21 / 21 | 100% | 44.27 | 502 / 504 |
uterus | 100% | 5260.66 | 170 / 170 | 99% | 45.34 | 455 / 459 |
thymus | 100% | 5537.72 | 653 / 653 | 99% | 35.03 | 599 / 605 |
skin | 100% | 7412.40 | 1809 / 1809 | 99% | 44.85 | 467 / 472 |
pancreas | 99% | 3208.47 | 326 / 328 | 99% | 36.77 | 177 / 178 |
kidney | 100% | 3952.96 | 89 / 89 | 99% | 30.12 | 889 / 901 |
brain | 98% | 2801.41 | 2594 / 2642 | 100% | 30.40 | 705 / 705 |
liver | 100% | 3532.88 | 226 / 226 | 98% | 25.34 | 397 / 406 |
adrenal gland | 100% | 5296.08 | 258 / 258 | 95% | 22.35 | 218 / 230 |
adipose | 100% | 6027.52 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 34.85 | 29 / 29 |
muscle | 100% | 16521.73 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 5450.29 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 34.73 | 45 / 45 |
blood vessel | 100% | 5327.63 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 6322.72 | 843 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 32.91 | 76 / 80 |
peripheral blood | 83% | 2562.79 | 775 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006281 | Biological process | DNA repair |
GO_0007283 | Biological process | spermatogenesis |
GO_0008283 | Biological process | cell population proliferation |
GO_0030097 | Biological process | hemopoiesis |
GO_0042254 | Biological process | ribosome biogenesis |
GO_0001701 | Biological process | in utero embryonic development |
GO_0034644 | Biological process | cellular response to UV |
GO_0006974 | Biological process | DNA damage response |
GO_0140627 | Biological process | ubiquitin-dependent protein catabolic process via the C-end degron rule pathway |
GO_1900087 | Biological process | positive regulation of G1/S transition of mitotic cell cycle |
GO_0045732 | Biological process | positive regulation of protein catabolic process |
GO_0097193 | Biological process | intrinsic apoptotic signaling pathway |
GO_0030853 | Biological process | negative regulation of granulocyte differentiation |
GO_2000819 | Biological process | regulation of nucleotide-excision repair |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_2000001 | Biological process | regulation of DNA damage checkpoint |
GO_0048511 | Biological process | rhythmic process |
GO_0042110 | Biological process | T cell activation |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0000082 | Biological process | G1/S transition of mitotic cell cycle |
GO_0035019 | Biological process | somatic stem cell population maintenance |
GO_0031464 | Cellular component | Cul4A-RING E3 ubiquitin ligase complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0080008 | Cellular component | Cul4-RING E3 ubiquitin ligase complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0160072 | Molecular function | ubiquitin ligase complex scaffold activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CUL4A |
Protein name | Cullin 4A Cullin-4A (CUL-4A) |
Synonyms | |
Description | FUNCTION: Core component of multiple cullin-RING-based E3 ubiquitin-protein ligase complexes which mediate the ubiquitination of target proteins . As a scaffold protein may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme . The E3 ubiquitin-protein ligase activity of the complex is dependent on the neddylation of the cullin subunit and is inhibited by the association of the deneddylated cullin subunit with TIP120A/CAND1 . The functional specificity of the E3 ubiquitin-protein ligase complex depends on the variable substrate recognition component . DCX(DET1-COP1) directs ubiquitination of JUN . DCX(DDB2) directs ubiquitination of XPC . DCX(DDB2) ubiquitinates histones H3-H4 and is required for efficient histone deposition during replication-coupled (H3.1) and replication-independent (H3.3) nucleosome assembly, probably by facilitating the transfer of H3 from ASF1A/ASF1B to other chaperones involved in histone deposition . DCX(DTL) plays a role in PCNA-dependent polyubiquitination of CDT1 and MDM2-dependent ubiquitination of p53/TP53 in response to radiation-induced DNA damage and during DNA replication . DCX(DTL) directs autoubiquitination of DTL . In association with DDB1 and SKP2 probably is involved in ubiquitination of CDKN1B/p27kip . Is involved in ubiquitination of HOXA9 . The DDB1-CUL4A-DTL E3 ligase complex regulates the circadian clock function by mediating the ubiquitination and degradation of CRY1 . A number of DCX complexes (containing either TRPC4AP or DCAF12 as substrate-recognition component) are part of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation . The DCX(AMBRA1) complex is a master regulator of the transition from G1 to S cell phase by mediating ubiquitination of phosphorylated cyclin-D (CCND1, CCND2 and CCND3) . The DCX(AMBRA1) complex also acts as a regulator of Cul5-RING (CRL5) E3 ubiquitin-protein ligase complexes by mediating ubiquitination and degradation of Elongin-C (ELOC) component of CRL5 complexes . With CUL4B, contributes to ribosome biogenesis . . |
Accessions | A0A0A0MR50 Q13619 ENST00000375440.9 [Q13619-1] A0A087WWN2 ENST00000451881.5 [Q13619-2] ENST00000617546.4 [Q13619-2] ENST00000326335.8 ENST00000375441.7 [Q13619-2] ENST00000488558.2 |